atomoxetine / Generic mfg. - LARVOL DELTA

Classification, diagnosis and therapy of attention deficit hyperactivity disorder (PubMed, Zh Nevrol Psikhiatr Im S S Korsakova) - "Age-related features of ADHD, gender differences are noted, the results of short-term and long-term courses of atomoxetine use are summarized, the results of randomized studies on the positive effect of the drug on the socialization of patients, academic performance and the possibility of correcting comorbid anxiety syndromes, autistic disorders and syncopal states are presented. In domestic practice of ADHD therapy, Atomoxetine it is a first-line drug."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Autism Spectrum Disorder • CNS Disorders • Genetic Disorders • Mood Disorders • Psychiatry • Sleep Disorder

Is the ADHD bomb about to explode? The impact of the medicalization of attention-deficit/hyperactivity disorder on its pharmacotherapy and institutional context in Hungary (PubMed, Orv Hetil) - "It provides a detailed discussion of the benefits and risks of methylphenidate, the issue of misuse, and the role of atomoxetine as an alternative. Orv Hetil. 2025; 166(49): 1935-1942."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Developmental deviations of structural connectivity in youths with ADHD predict symptom and treatment outcomes. (PubMed, bioRxiv) - "Baseline deviations also predicted 12-week treatment response to atomoxetine, but not methylphenidate, and follow-up imaging revealed treatment-related reductions in deviation. Together, these findings identify SC deviation as a robust developmental biomarker with prognostic and theragnostic relevance for ADHD, supporting precision care through risk stratification, individualized pharmacotherapy selection, and objective monitoring of treatment effects."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Pharmacological Treatment Targeting Endotypic Traits of Obstructive Sleep Apnea (clinicaltrials.gov) - P4 | N=45 | Completed | Sponsor: China Medical University Hospital | Recruiting ➔ Completed | N=132 ➔ 45

Enrollment change • Trial completion • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder

Progress in the pharmacological management of vasovagal syncope. (PubMed, Expert Rev Clin Pharmacol) - "Atomoxetine is under investigation. Some benefit from fludrocortisone, midodrine, or serotonin-specific reuptake inhibitors. Almost all patients eventually stop fainting, and invasive treatments should be used last and for the very few highly afflicted patients who do not improve with safer measures."

Journal • Review • Hypotension • Psychiatry

Progressive Relaxation and Psychoeducation in Patients With Hematological Malignancies (clinicaltrials.gov) - P=N/A | N=75 | Not yet recruiting | Sponsor: Necmettin Erbakan University

New trial • Hematological Malignancies • Oncology

Benefits and harms of ADHD interventions: umbrella review and platform for shared decision making. (PubMed, BMJ) - "This review provides updated evidence to inform patients, practitioners, and guideline developers how best to manage ADHD symptoms. The online platform should facilitate the implementation of shared decision making in daily practice."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

An Efficient Neural Network of Cooperating Serotonergic and Noradrenergic Neurons in Modulating SUDEP (AES 2025) - "Clinical Translation PotentialWith its unique integration of circuit neuroscience and translational pharmacology, this work promises to redefine clinical approaches to SUDEP prevention. Using the SUDEP-prone DBA/1 mouse model, we employed integrated approaches: pharmacological interventions (5-hydroxytryptophan, atomoxetine, venlafaxine), in vivo calcium imaging, and optogenetics. Targeted microinjections of receptor antagonists (ketanserin: 5-HT2A; prazosin: NE α-1) into the pre-Bötzinger complex (PBC) assessed local receptor contributions. We demonstrate, for the first time, a robust synergistic interaction between 5-HT and NE in mitigating S-IRA and preventing SUDEP... This study establishes the DR-LC-PBC pathway as a critical network for the synergistic protective action of 5-HT and NE against S-IRA and SUDEP. We identify 5-HT2A and NE α-1 receptors within the PBC as key therapeutic targets. These findings provide a mechanistic foundation for developing novel..."

Late-breaking abstract • CNS Disorders • Epilepsy

Fatal atomoxetine overdose in Japan: a forensic autopsy case report. (PubMed, Int J Legal Med) - "Cardiac blood screening, performed using a semi-quantitative analysis, detected 7-aminoflunitrazepam, 7-aminonitrazepam, allylisopropylacetylurea, aripiprazole, atomoxetine, bromazepam, and suvorexant. The atomoxetine and bromazepam concentrations were 23.2 and 0.71 µg/mL in femoral blood and 24.0 and 0.78 µg/mL in cardiac blood. In conclusion, the cause of death was primarily due to acute atomoxetine intoxication, with bromazepam excluded as a direct contributing factor."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Role of the Noradrenergic System in the Regulation of Learning Dynamics: Evaluation of the Effect of a Low-dose Selective Noradrenaline Reuptake Inhibitor (NOISYXETINE) (clinicaltrials.gov) - P=N/A | N=160 | Recruiting | Sponsor: Centre Hospitalier St Anne

New trial

Atomoxetine Drug Properties for Repurposing as a Candidate Alzheimer's Disease Therapeutic Agent. (PubMed, ACS Pharmacol Transl Sci) - "The goal of this review is to assess atomoxetine for repurposing in AD based on its ability to improve cognition, regulate NE, impact AD biomarkers, and preserve LC neuronal function, with suitable pharmacokinetics, drug metabolism, and safety based on analysis of clinical and preclinical studies. Evidence for neuroprotective effects of atomoxetine in the early stage of AD at clinically safe doses with suitable pharmaceutical properties supports its candidacy as a repurposed drug for AD therapeutics."

Journal • Review • ADHD (Impulsive Aggression) • Alzheimer's Disease • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Attention deficit hyperactivity disorder: pharmacotherapy in special situations (PubMed, Zh Nevrol Psikhiatr Im S S Korsakova) - "The possibilities of using atomoxetine in the comorbidity of ADHD with destructive behavior, anxiety disorders, sleep disorders, nocturnal enuresis, tics, stuttering, dyslexia, as well as the effect of atomoxetine on sluggish cognitive tempo and executive functioning are considered. The approaches to optimal dosing and minimization of adverse events during atomoxetine treatment are discussed."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Cognitive Disorders • Developmental Disorders • Mood Disorders • Movement Disorders • Psychiatry • Sleep Disorder • Urinary Incontinence

Letter: Author's Reply to: "Refining Atomoxetine Research for Adolescent NSSI". (PubMed, J Child Adolesc Psychopharmacol) - No abstract available

Journal

Alterations in the striatum and hippocampus of juvenile rats induced by the chronic use of different doses of ADHD drug atomoxetine (Neuroscience 2025) - "In addition, in the regions mentioned earlier, the three different doses of ATX increased oxidative stress, as seen by elevated superoxide production indicated by dihydroethidium fluorescent signals in both brain areas. We conclude that the chronic use of three different doses of ATX produced increasing neuronal damage which would trigger an increase in the neuroinflammation process and consequently an increasing of oxidative stress in both the striatum and the hippocampus."

Preclinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry • GFAP

An efficient neural network of cooperating serotonergic and noradrenergic neurons in modulating sudden unexpected death in epilepsy. (PubMed, Int J Biol Sci) - "Through a combination of pharmacological interventions, calcium signal recordings, and optogenetics, results show that elevating 5-HT and NE levels via 5-hydroxytryptophan and the norepinephrine reuptake inhibitor atomoxetine significantly reduced SUDEP incidence, with evidence of a robust synergistic interaction. Furthermore, venlafaxine, a selective serotonin-norepinephrine reuptake inhibitor, enhances the cooperative regulation of 5-HT and NE, further supporting their combined protective role...Targeted administration of the 5-HT2A/NE α-1 receptor antagonist and agonist into the PBC reveal their pivotal roles in mediating the protective effects of 5-HT and NE. Our study reveals that serotonergic and noradrenergic systems synergistically regulate SUDEP, and further identifies that the DR-LC-PBC neural circuit exerts a protective effect through activation of 5-HT2A and NE-α1 receptors within the PBC."

Journal • CNS Disorders • Epilepsy

Letter: Considerations for Refining Research of Atomoxetine in Adolescents with Nonsuicidal Self-Injury. (PubMed, J Child Adolesc Psychopharmacol) - No abstract available

Journal

Atomoxetine-Induced Spontaneous Seminal Discharge in Adult ADHD With Trichotillomania: Case Report and Literature Review. (PubMed, Int Med Case Rep J) - "This case report describes a 37-year-old man diagnosed initially with trichotillomania and generalized anxiety disorder and started on fluoxetine 20 mg for six weeks with substantial symptoms improvement of both disorders. After three months of monitoring, we re-evaluated ADHD and trichotillomania, adjusted the therapy, and observed that there was no recurrence of symptoms. This instance shows the importance of careful monitoring for rare side effects in people with complex psychiatric comorbidities."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Bipolar Disorder • CNS Disorders • Endocrine Cancer • General Anxiety Disorder • Mood Disorders • Psychiatry

Exposures to attention deficient hyperactivity disorder medications reported to the New South Wales Poisons Information Centre (2014-2023): A retrospective study. (PubMed, Aust N Z J Psychiatry) - "Exposures to attention deficit hyperactivity disorder medications present a growing public health issue. Rates have risen annually over the past decade, and the majority require medical attention, placing strain on healthcare resources. There are notable differences in exposure patterns among affected age groups. This highlights the need for targeted preventive measures focused on both quality use of the medication being prescribed as well as considering the circumstances and safety of the individual and household."

Journal • Retrospective data • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Attention-deficit hyperactivity disorder medication use in pregnancy and risk of miscarriage. (PubMed, Br J Psychiatry) - "ADHD medication use during pregnancy is associated with increased miscarriage risk. However, filled prescriptions may not reflect actual use. Further research is needed to clarify these associations and refine risk estimates."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

A randomised controlled trial to evaluate the clinical and cost-effectiveness of Stimulant compared with Non-stimulant medication for adults with Attention-deficit/hyperactivity disorder and a history of Psychosis or biPolar disordER: SNAPPER. (PubMed, Trials) - "Given that untreated ADHD is associated with poor clinical outcomes, unemployment and criminal justice system involvement, clear evidence in this area is likely to improve recovery for individuals with ADHD and a history of SMI, reducing costs for the individual, the NHS and society."

HEOR • Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Bipolar Disorder • CNS Disorders • Developmental Disorders • Mood Disorders • Psychiatry

Exploring Ferroptosis-Related Genes in Depression: Insights Into Molecular Mechanisms and Potential Therapies. (PubMed, Int J Gen Med) - "We identified five potential small-molecule compounds (VX-702, gossypol, atomoxetine, TWS-119, and ibudilast) that may target these ferroptosis-related pathways...This study provides evidence supporting the involvement of ferroptosis-related mechanisms in depression and proposes a integrative treatment strategy combining targeted molecular interventions with TCM approaches. The findings offer new perspectives for developing therapeutic interventions, particularly for treatment-resistant depression."

Journal • CNS Disorders • Depression • Inflammation • Mood Disorders • Psychiatry

Therapeutic Reference Ranges for ADHD Drugs in Blood of Children and Adolescents: A Systematic Review by the AGNP TDM-Task Force. (PubMed, Pharmacopsychiatry) - "This study aimed to establish preliminary therapeutic reference ranges for methylphenidate (MPH), d-amphetamine (d-AMP), atomoxetine (ATX), and guanfacine (GFC), based on a systematic review of the existing relevant literature.Therapeutic reference ranges were calculated based on blood concentrations measured in responder children and adolescents with ADHD. For GFC, only one study was eligible, with a mean blood concentration of 7.5 ng/mL in responders.The results provide preliminary recommendations that can serve as reference values for therapeutic drug monitoring in children and adolescents treated with MPH, AMP, ATX, and GFC. Further research is needed to validate or refine the proposed therapeutic ranges."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Clinical Features of Adults With ADHD, Focusing on Their Adherence to Medication (AACAP 2025) - "We examined the adherence and persistence of those who received pharmacotherapy for ADHD, which was with either methylphenidate or atomoxetine. From the results of this study, it could be inferred that misuse and abuse of stimulants may not be common for those who receive a proper diagnosis and an adequate prescription. The bigger concern in clinical practice for adults with ADHD is that they have low compliance for treatment. Clinicians treating adults with ADHD should put more emphasis on adherence to ADHD medication than on abuse or misuse of ADHD medications.ADHD, TREAT, PPC"

Adherence • Clinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Examining the Effects of Atomoxetine Alone vs Atomoxetine Combined With Risperidone in a Sample of Egyptian Children With ADHD (AACAP 2025) - "Patients with the attention deficit variant responded well to atomoxetine. Patients with the attention-deficit/hyperactivity variant responded well to atomoxetine/antipsychotic (risperidone) combination. Patients with the hyperactivity variant showed good response to antipsychotics (risperidone)."

Clinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Aggression, Mood Dysregulation, and Treatment Response in Youth With ADHD (AACAP 2025) - "This presentation discusses findings from a crossover study of ADHD youth treated with osmotic-controlled-release oral delivery system (OROS)-methylphenidate (MPH) and atomoxetine (ATX). Stimulants and nonstimulants can each have a role in the treatment of aggression and mood dysregulation in ADHD youth, with interrelationships among ADHD symptoms, aggression, and mood dysregulation contributing to overall response.TREAT, AGG, ADHD"

ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Behavior Disorders • CNS Disorders • Psychiatry